Congenital Heart Defect Devices Market By Device Type (Diagnostic Devices, Surgical Devices, Therapeutic Devices); By Application (Diagnosis, Surgical Intervention, Long-Term Management); By End User (Pediatric Hospitals, General Hospitals, Cardiac Care Centers, Ambulatory Surgical Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Congenital Heart Defect Devices Market: Advanced Cardiac Devices for Congenital Heart Defect Treatment and Intervention

The Global Congenital Heart Defect Devices Market was valued at USD 6.5 billion in 2025, with a projected reach of USD 9.8 billion by 2032 and a 7.2% CAGR.

 

he FDA has approved several breakthrough minimally invasive devices for congenital heart defects (CHDs), including Medtronic’s Harmony Transcatheter Pulmonary Valve for right ventricular outflow tract dysfunction, the Minima Growth Stent designed to expand as pediatric patients grow, and the Occlutech ASD Occluder for transcatheter closure of atrial septal defects. These approvals reflect a shift toward less invasive structural heart solutions, while the broader clinical pipeline is increasingly focused on regenerative approaches such as cell and gene therapies, including bone marrow–derived mesenchymal stem cells and induced pluripotent stem cell–derived cardiomyocytes for cardiac repair.

 

Emerging research is also advancing myocardial regeneration strategies using growth factors like neuregulin-1 (NRG-1) to support cardiomyocyte survival and repair, along with protein-targeted approaches such as LRRC10 expression to stimulate heart muscle regeneration. Together, these developments highlight a dual innovation pathway in CHD treatment: continued expansion of minimally invasive implantable devices alongside next-generation biologics aimed at restoring or regenerating damaged cardiac tissue.

 

What are congenital heart defect devices and why is demand increasing?

Congenital heart defect devices include diagnostic equipment, implants, catheter-based systems, surgical products, and devices used in the continued management of structural heart abnormalities present from birth. The market covers diagnostic imaging and screening devices as well as ASD, VSD and PDA occluders, congenital stents, pulmonary valves, conduits, and related cardiac devices used during intervention and follow-up.

Demand is increasing because congenital heart disease is increasingly managed as a lifelong condition rather than only a pediatric disorder. Better diagnosis identifies abnormalities earlier, while improved survival creates a growing population of adolescents and adults requiring cardiac imaging, follow-up, and repeat structural interventions. The American Heart Association's latest guidance emphasizes continued specialized care for adults with congenital heart disease.

 

How is the patient population supporting the Congenital Heart Defect Devices Market?

Congenital heart defects affect nearly 1% of U.S. births, or about 40,000 babies annually. About one in four babies born with a heart defect has a critical CHD and generally requires surgery or another procedure during the first year of life. This provides a recurring pediatric demand base for screening, diagnostic imaging, surgery, catheter intervention, and follow-up devices.

Globally, approximately 2.3 million children were born with CHD in 2023, while about 16 million people were living with the condition. In the U.S., previous population estimates identified approximately 2.4 million people living with CHD. The rising survivor population is particularly important because repaired congenital disease can still require long-term imaging, rhythm assessment, valve replacement, stenting, or further surgery.

Diagnostic demand begins before or shortly after birth. CDC identifies echocardiography as an important test for confirming suspected CHD, while pulse oximetry is used for newborn screening for critical congenital heart defects. All U.S. states and Washington, D.C. had adopted critical-CHD newborn screening programs by 2018.

 

How is the Congenital Heart Defect Devices Market segmented by device type?

Diagnostic Devices accounted for an estimated 42.0% market share in 2025, representing approximately USD 2.73 billion. The segment is projected to reach about USD 3.92 billion by 2032, at a CAGR of 5.3%. Echocardiography, fetal cardiac imaging, MRI, ECG systems, pulse oximetry, and related diagnostic equipment support prenatal detection, newborn screening, procedural planning, and continued surveillance. Echocardiography remains especially important because it can identify structural abnormalities and evaluate cardiac function without exposing pediatric patients to radiation.

Surgical Devices held an estimated 36.0% share in 2025, equivalent to approximately USD 2.34 billion, and are forecast to reach USD 3.63 billion by 2032, expanding at a CAGR of 6.5%. The segment includes septal and PDA occluders, congenital stents, valves, conduits, patches, and other devices used during surgical or catheter-based correction. Procedure volume remains substantial: the Society of Thoracic Surgeons recorded 144,919 congenital operations at 114 North American sites during 2019–2022.

Therapeutic Devices represented approximately 22.0% of the market in 2025, or around USD 1.43 billion. Revenue is projected to reach approximately USD 2.25 billion by 2032, at a CAGR of 6.7%. Growth is linked to the expanding population living with repaired complex CHD and requiring repeat valve, rhythm-management, or other device-supported care. The 2025 adult CHD guideline reinforces the need for routine specialized follow-up as more patients survive into adulthood.

 

Which applications account for the largest share of market revenue?

Diagnosis led the application segment with an estimated 43.0% share in 2025, generating approximately USD 2.80 billion. It is projected to reach USD 3.92 billion by 2032, at a CAGR of 5.0%. Demand is supported by fetal echocardiography, newborn pulse-oximetry screening, pediatric echocardiography, MRI, and repeated cardiac imaging. Early identification of serious congenital defects can also influence delivery planning and the timing of intervention.

Surgical Intervention accounted for approximately 36.0% of 2025 revenue, or USD 2.34 billion, and is expected to reach about USD 3.63 billion by 2032, growing at a CAGR of 6.5%. Demand comes from open congenital surgery as well as catheter-based closure, stenting, and valve replacement. NCDR data recorded 1,587 attempted catheter closures of PDA in infants weighing 2 kg or less between April 2016 and June 2021, including 1,549 successful implants.

Long-Term Management represented an estimated 21.0% share in 2025, valued at approximately USD 1.37 billion. It is the fastest-growing application and is projected to reach around USD 2.25 billion by 2032, at a CAGR of 7.4%. Adults with repaired congenital disease may require lifelong imaging, rhythm monitoring, repeat procedures, and specialist assessment. Current ACC/AHA guidance recommends routine care involving adult congenital heart disease centers and specialists.

 

Which end users generate the strongest demand for congenital heart defect devices?

Pediatric Hospitals accounted for the largest end-user share at approximately 38.0% in 2025, representing USD 2.47 billion. Revenue is forecast to reach about USD 3.53 billion by 2032, at a CAGR of 5.2%. Their leadership reflects the concentration of neonatal diagnosis, pediatric catheterization, congenital surgery, intensive care, and complex structural procedures in specialist children's hospitals.

General Hospitals represented approximately 24.0% of the market in 2025, or USD 1.56 billion, and are projected to generate around USD 2.25 billion by 2032, at a CAGR of 5.4%. These hospitals participate mainly through diagnostic imaging, emergency diagnosis, adult congenital follow-up, and referral pathways into specialized cardiac programs.

Cardiac Care Centers held an estimated 29.0% share in 2025, corresponding to approximately USD 1.89 billion. The segment is forecast to reach USD 3.14 billion by 2032, growing at a CAGR of 7.5%, making it the fastest-growing end-user category. Growth reflects the increasing number of adults requiring specialist congenital follow-up and repeat structural interventions. The American Heart Association notes that adults with CHD benefit from continued care through specialized adult congenital heart disease centers.

Ambulatory Surgical Centers accounted for an estimated 9.0% share in 2025, worth approximately USD 0.59 billion, and are projected to reach about USD 0.88 billion by 2032, at a CAGR of 6.0%. Their role remains smaller because complex congenital procedures generally require hospital-based cardiac surgery, catheterization, anesthesia, and intensive-care resources.

 

How does the Congenital Heart Defect Devices Market differ by geography?

North America led the global market with an estimated 39.0% share in 2025, representing approximately USD 2.54 billion. Revenue is projected to reach about USD 3.63 billion by 2032, at a CAGR of 5.2%. The region benefits from established newborn screening, specialized pediatric cardiac hospitals, adult congenital centers, and extensive surgical and interventional capability. The STS Congenital Heart Surgery Database continues to capture substantial procedure activity across participating centers.

Europe held approximately 28.0% of the market in 2025, equivalent to USD 1.82 billion, and is forecast to reach about USD 2.65 billion by 2032, at a CAGR of 5.5%. Demand is supported by established congenital cardiac programs and expanding access to transcatheter devices. Medtronic received CE Mark for the Harmony transcatheter pulmonary valve in January 2025 and reported more than 2,200 patients implanted with the system at the time.

Asia-Pacific accounted for an estimated 24.0% share in 2025, or approximately USD 1.56 billion, and is projected to reach USD 2.65 billion by 2032, growing at a CAGR of 7.8%. It is the fastest-growing regional market in the model, supported by a large patient population, improving diagnosis, expanding pediatric cardiac centers, and increasing access to catheter-based procedures.

Latin America represented approximately 5.0% of market revenue in 2025, valued at USD 0.33 billion, and is projected to reach around USD 0.49 billion by 2032, at a CAGR of 6.0%. Expansion of pediatric cardiac services and diagnostic access is gradually increasing the number of children entering specialist treatment pathways.

Middle East & Africa accounted for approximately 4.0% of the market in 2025, representing USD 0.26 billion, and is forecast to reach about USD 0.39 billion by 2032, at a CAGR of 6.0%. Growth depends heavily on specialist cardiac infrastructure because complex congenital procedures require multidisciplinary hospital capabilities.

 

How are catheter-based procedures changing device demand?

The expansion of catheter-based procedures is shifting part of congenital cardiac care away from repeat open-heart surgery. ASD and PDA occluders, congenital stents, and transcatheter pulmonary valves allow selected patients to receive structural correction through cardiac catheterization.

This change is particularly important for patients requiring later-life pulmonary-valve intervention. Medtronic's Harmony system is approved for selected patients with severe pulmonary regurgitation involving a native or surgically repaired right-ventricular outflow tract, and FDA records continue to show active regulatory supplements for the system.

Abbott has also expanded catheter intervention into very small patients. Its Amplatzer Piccolo Occluder, approved in the U.S. in 2019 for PDA closure in selected premature infants, had been used in more than 3,000 premature babies by the company's 2023 disclosure.

 

Which companies are shaping competition in the Congenital Heart Defect Devices Market?

Abbott Laboratories: Dominating Congenital Structural Heart Innovation with Amplatzer & Piccolo Leadership

Abbott participates through its Amplatzer congenital structural-heart portfolio, including septal and PDA occlusion devices. Piccolo gives the company a differentiated position in premature-infant PDA closure.

 

W. L. Gore & Associates: Strengthening Global ASD Closure Leadership with CARDIOFORM Device Excellence

Gore competes in ASD closure through the CARDIOFORM ASD Occluder. Current company material reports more than 15,000 devices sold globally after more than 10 years of clinical use, strengthening Gore's presence in transcatheter septal closure.

 

Medtronic: Expanding Transcatheter Pulmonary Valve Dominance with Harmony & Melody Platforms

Medtronic's congenital portfolio includes the Harmony and Melody transcatheter pulmonary-valve systems. European CE Mark for Harmony in 2025 expanded its commercial reach among patients with severe pulmonary regurgitation following congenital repair.

 

Edwards Lifesciences: Advancing Next-Gen RVOT Solutions in Congenital Heart Reintervention

Edwards participates in transcatheter pulmonary-valve replacement through the SAPIEN 3 platform with the Alterra Adaptive Prestent, targeting selected patients with native or surgically repaired RVOT anatomy. The product broadens Edwards' structural-heart presence into congenital reintervention.

 

Occlutech: Accelerating Global ASD Closure Expansion with Strong International Device Adoption Base

Occlutech strengthened competition in U.S. ASD closure after FDA approval in January 2024. The company reported more than 90,000 ASD devices sold outside the U.S. before its American launch, giving it an established international clinical base when entering the U.S. market.

 

What factors could limit market expansion?

Market growth remains dependent on access to specialist congenital cardiac care. Complex cases require pediatric cardiologists, congenital surgeons, imaging specialists, catheter laboratories, anesthesia, intensive care, and long-term follow-up, keeping advanced procedures concentrated in major centers.

Device eligibility also varies considerably by anatomy. Many mild congenital defects need observation rather than intervention, while some complex cases require surgery instead of a catheter-delivered implant. Overall CHD prevalence therefore remains substantially larger than the population receiving specific congenital devices.

Long-term performance is another important consideration because many patients receive treatment early in life and remain under follow-up for decades. Hospitals therefore place strong value on clinical experience, durability, the ability to manage later interventions, and continued imaging compatibility.

 

What will define the next phase of the Congenital Heart Defect Devices Market?

Future demand will increasingly combine early diagnosis with lifelong congenital cardiac management. Prenatal imaging and newborn screening continue to identify patients entering pediatric care, while improved survival enlarges the adult congenital population requiring imaging, monitoring, valve replacement, and repeat intervention.

The long-term management application, cardiac care center end-user segment, and Asia-Pacific region are expected to record some of the strongest growth within the modeled segmentation. At the same time, expanding catheter-based treatment into smaller patients and more varied congenital anatomy is creating additional opportunities for occluders, stents, valves, and related devices.

The Congenital Heart Defect Devices Market is consequently shifting from a market centered mainly on childhood diagnosis and surgery toward a broader lifetime-care model spanning prenatal detection, pediatric correction, structural reintervention, adult congenital care, and continuous cardiac surveillance.

 

Which sources support the market analysis?

Public Health and Patient Population: CDC — approximately 40,000 U.S. CHD births annually and about one-quarter classified as critical CHD. World Heart Federation — approximately 2.3 million CHD births and 16 million people living with CHD globally.

Diagnosis and Long-Term Care: CDC — echocardiography and newborn pulse oximetry are central to CHD detection. American Heart Association and American College of Cardiology — congenital heart disease increasingly requires specialized lifelong follow-up.

Procedures and Devices: Society of Thoracic Surgeons — substantial congenital surgical activity across North American participating centers. FDA — ongoing regulatory evidence for transcatheter congenital devices including pulmonary-valve systems.

Company Developments: Abbott — more than 3,000 premature babies treated with Piccolo by its 2023 disclosure. Gore — more than 15,000 CARDIOFORM ASD devices sold globally. Medtronic — more than 2,200 Harmony implants reported when CE Mark was announced. Occlutech — more than 90,000 ASD devices sold outside the U.S. before its 2024 U.S. entry.

 

Congenital Heart Defect Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 6.5 Billion
Revenue Forecast in 2032	USD 9.8 Billion
Overall Growth Rate	CAGR of 7.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Device Type, By Application, By End User, By Geography
By Device Type	Diagnostic Devices, Surgical Devices, Therapeutic Devices
By Application	Diagnosis, Surgical Intervention, Long-Term Management
By End User	Pediatric Hospitals, General Hospitals, Cardiac Care Centers, Ambulatory Surgical Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prevalence of congenital heart defects and growing survivor population requiring lifelong cardiac care Increasing adoption of minimally invasive catheter-based congenital heart interventions Advancements in pediatric cardiac imaging, structural heart devices, and transcatheter technologies
Customization Option	Available upon request